People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Healthtech, Biotechnology, Other Technology, Software / Tech, Retailing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tula Health, Inc. | — | Healthtech | Series B | $57.0M | $37.2M | 2018 |
| Causeway Therapeutics Ltd | — | Biotechnology | Series A | $14.3M | $147.5M | 2023 |
| Betaliq Inc | — | Biotechnology | Series A | $6.4M | $1.4M | 2025 |
| Clean Filtration Technologies Inc | — | Other Technology | Seed | $5.5M | $68.1M | 2010 |
| Silk Labs, Inc. | — | Other Technology | Seed | $2.2M | $75.9M | 2015 |
| Research Blocks Technologies, Inc. | — | Software / Tech | Pre-Seed | $1.0M | $19.4M | 2021 |
| Mountain Spring Technologies, Inc. | — | Software / Tech | Pre-Seed | $600K | $2.0M | 2025 |
| Periodic, LLC | — | Retailing | Pre-Seed | $270K | $495K | 2025 |
| trUSx, Inc. | — | Other Technology | Pre-Seed | $250K | $9.5M | 2020 |
Christopher Jones at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Jones on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Miller | 1 | 29 |
| Jeffrey Peterson | 1 | 10 |
| Declan Doogan | 1 | 6 |
| BARRY BUTLER | 1 | 6 |
| Austin Walters | 1 | 4 |
| Richard V Cancro | 1 | 2 |
| Jerry Henley | 1 | 2 |
| Alan Hall | 1 | 2 |
| Neil Gibson | 1 | 2 |
| Eric Clark | 1 | 2 |
| Timothy Maguire | 1 | 2 |
| David Armour | 1 | 1 |
| Alexander Picket | 1 | 1 |
| Derek Gilchrist | 1 | 1 |
| Robert DeYoung | 1 | 1 |
| Mark V Powell | 1 | 1 |
| Ramnath V Lakshmi-Ratan | 1 | 1 |
| Justin Kim | 1 | 1 |
| Lance Cleveland | 1 | 1 |
| David Derrick | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.